Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

- Approval of Second IND Marks Major Corporate Milestone and Advances

Clinical Program -

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is repurposing for the treatment of endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina recently completed a global licensing agreement to make, develop and commercialize products, including MPI-676, under AstraZeneca's IP and know-how regarding the use of AIs in combination with estrogen and progestin to treat endometriosis.

"This IND for MPI-676 marks another major milestone in our robust clinical program focused on addressing women's reproductive system disorders," said James Symons, Ph.D., Vice President, Clinical Development, Meditrina Pharmaceuticals, Inc. "Based on the encouraging proof of concept and strong safety data established for MPI-676, we look forward to selecting the dose for Phase III pivotal trials, which will be at a dose lower than for which AstraZeneca has already established two-year chronic use safety data in their breast cancer prevention trials and is cited in the anastrozole product label. These data will advance development of MPI-676 and help us bring this important new treatment to women suffering from endometriosis, a painful and debilitating condition."

This US-based, multi-center, placebo-controlled, double-blinded study will identify the maximally efficacious dose of MPI-676 to investigate in the pivotal Phase III program. The Phase IIb dose ra
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ICK,N.J.,Nov.25/PRNewswire/--SwissrayInternational...y( ddR )systems,announcedtodaythatitsoperationshav...iewtowardsgrowingSwissray,smedicalimagingbrand.The...y,aswellascontractsandinventory.After25yearsofsucc...loftechnologicaladvancementswithstableandsteadygro...
(Date:11/25/2009)...v.25/PRNewswire/--Reportlinker.comannouncesthatane..., IntranasalDrugDelivery-USMarketTrends&Ana...asal-Drug-Delivery---US-Market-Trends--Analysis.ht...ssinganexpansionoftherapeuticapplicationsfromthede...veryofsystemictherapeuticdrugs.Thefutureofthetechn...
(Date:11/24/2009)...,Nov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgi...utoaccident,wasactuallyfullyconsciousandawakedurin...ent.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillus...onscanunlockcommunication. ,, WHEN:GoodMorningA...ww.dynavoxtech.com ,, WHO:RomHoubenswasanen...
Breaking Medicine Technology:Swissray International Announces New Ownership 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Dogs and 2 Year Olds on Same Mental Plane 54041 1Dogs and 2 Year Olds on Same Mental Plane 54041 2Dogs and 2 Year Olds on Same Mental Plane 54041 3NCCN Stresses Importance of PSA Testing in High Risk Men 54037 1NCCN Stresses Importance of PSA Testing in High Risk Men 54037 2NCCN Stresses Importance of PSA Testing in High Risk Men 54037 3NCCN Stresses Importance of PSA Testing in High Risk Men 54037 4NCCN Stresses Importance of PSA Testing in High Risk Men 54037 5AlphaRx Receives China Patent on Its Drug Delivery Platform 54033 1AlphaRx Receives China Patent on Its Drug Delivery Platform 54033 2
(Date:11/26/2009)...ears, the number of Americans living with diabetes...in 2009 to 44.1 million in 2034. Over the same per...ng from $113 billion to $336 billion, even with no...s based at the University of Chicago report in the... of those with diabetes covered by Medicare will r...
(Date:11/26/2009)... big or too heavy can lead to strains or worse , ...here may be nothing wrong with stuffing your turke...he same thing with your suitcase as you pack for h...eated in 2008 in U.S. hospital emergency rooms, do...es for luggage-related injuries, such as muscle st...
(Date:11/26/2009)... No more letters from the North Pole, Texts...t messages from Santa , N...operational efficiencies at the North Pole Santa C...ldren all over the globe informed of his Christmas...quo;s research department have identified a large ...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a lea...na, today announced the expansion of its services ...st, Dr. Doug Macmillan. , ... is pleased to announce that Dr. Doug Macmillan, a...ted an additional advanced training seminar. RTDe...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free n...Yaz and Yasmin birth control pills who have suffer...m, Stroke, Heart Attack or other related cardiac i...call toll free at 1-800-856-6405 or go to the firm...fill out an online case evaluation form. , ...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
...ansaction brings total investment in low-income ur... more than $200 million., WOODLAND HILLS, Calif.,...ounced today that a recent $10.6 million investmen...lion through its Investment in a Healthy Californi...
...,s never as good as the body,s own at delivering o...Y, Oct. 8 (HealthDay News) -- Researchers have spo...ood stored in blood banks less effective at delive...m. , Though unlikely to change current clinical pr...
...LLEVUE, Wash., Oct. 8 The Washington State,Veteri...ished Veterinary,Staff Award to Karen Henricksen, ...eived the award in recognition of her dedication a...cation needed with the pets, owners., Henricksen ...
...LLEVUE, Wash., Oct. 8 The Washington State,Veteri...rinarian of the,Year Award to veterinary surgeon, ....com/cgi-bin/prnh/20070613/WSVMALOGO ), Dr. Sini... helping inform the public of the role and capabil...
...If you,re like most, you eat worst at healthy rest...s often prompt consumers to treat themselves to hi...when they eat at fast-food restaurants that make n...arch , found that many people also tend to underes...
...Los Angeles, October 8, 2007 High-risk teenagers ...tion programs reduce their drug use by approximate...ts a study led by researchers at the University of... disseminate information about the bad effects of ...
Other Medicine News:Health News:Blue Cross of California Invests $10.6 Million in Community Clinics Through the Investment in a Healthy California Program 2Health News:Blue Cross of California Invests $10.6 Million in Community Clinics Through the Investment in a Healthy California Program 3Health News:Studies Probe Weaknesses in Donated Blood 2Health News:Studies Probe Weaknesses in Donated Blood 3Health News:Studies Probe Weaknesses in Donated Blood 4Health News:Seattle Surgeon Named 2007 Veterinarian of the Year 2Health News:'Healthy' restaurants help make us fat, says a new Cornell study 2Health News:Friends help friends avoid drug use 2
Avant E-Z Rack Premium Low Binding Microreach Pipet Tips
Finntip Wide 100-1000 L
Finntip 250 Universal Refill Pack
MBP 200G Genomic Tip
Medicine Products: